Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in untreated metastatic uveal melanoma
NCT02626962Phase 2Completed
- Start
- Apr 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in Uveal melanoma (UM). Primary endpoint: Overall Survival at 12 months. Started Apr 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02626962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626962.